Literature DB >> 18612139

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

Thomas Brzoska1, Thomas A Luger, Christian Maaser, Christoph Abels, Markus Böhm.   

Abstract

Alpha-MSH is a tridecapeptide derived from proopiomelanocortin. Many studies over the last few years have provided evidence that alpha-MSH has potent protective and antiinflammatory effects. These effects can be elicited via centrally expressed melanocortin receptors that orchestrate descending neurogenic antiinflammatory pathways. alpha-MSH can also exert antiinflammatory and protective effects on cells of the immune system and on peripheral nonimmune cell types expressing melanocortin receptors. At the molecular level, alpha-MSH affects various pathways implicated in regulation of inflammation and protection, i.e., nuclear factor-kappaB activation, expression of adhesion molecules and chemokine receptors, production of proinflammatory cytokines and mediators, IL-10 synthesis, T cell proliferation and activity, inflammatory cell migration, expression of antioxidative enzymes, and apoptosis. The antiinflammatory effects of alpha-MSH have been validated in animal models of experimentally induced fever; irritant and allergic contact dermatitis, vasculitis, and fibrosis; ocular, gastrointestinal, brain, and allergic airway inflammation; and arthritis, but also in models of organ injury. One obstacle limiting the use of alpha-MSH in inflammatory disorders is its pigmentary effect. Due to its preserved antiinflammatory effect but lack of pigmentary action, the C-terminal tripeptide of alpha-MSH, KPV, has been delineated as an alternative for antiinflammatory therapy. KdPT, a derivative of KPV corresponding to amino acids 193-195 of IL-1beta, is also emerging as a tripeptide with antiinflammatory effects. The physiochemical properties and expected low costs of production render both agents suitable for the future treatment of immune-mediated inflammatory skin and bowel disease, fibrosis, allergic and inflammatory lung disease, ocular inflammation, and arthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612139     DOI: 10.1210/er.2007-0027

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  89 in total

1.  Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

Authors:  F M Rabey; R S V S Gadepalli; S Diano; Q Cheng; T Tabrizian; D Gailani; J M Rimoldi; Z Shariat-Madar
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Morph-specific genetic and environmental variation in innate and acquired immune response in a color polymorphic raptor.

Authors:  Laura Gangoso; Alexandre Roulin; Anne-Lyse Ducrest; Juan Manuel Grande; Jordi Figuerola
Journal:  Oecologia       Date:  2015-04-04       Impact factor: 3.225

3.  Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Authors:  Bo Xiao; Zhigang Xu; Emilie Viennois; Yuchen Zhang; Zhan Zhang; Mingzhen Zhang; Moon Kwon Han; Yuejun Kang; Didier Merlin
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

4.  Melanocortin type 4 receptor-mediated inhibition of A-type K+ current enhances sensory neuronal excitability and mechanical pain sensitivity in rats.

Authors:  Yuan Zhang; Dongsheng Jiang; Hua Li; Yufang Sun; Xinghong Jiang; Shan Gong; Zhiyuan Qian; Jin Tao
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

5.  An α-MSH analog in erythropoietic protoporphyria.

Authors:  Thomas A Luger; Markus Böhm
Journal:  J Invest Dermatol       Date:  2015-04       Impact factor: 8.551

Review 6.  The therapeutic applications of antimicrobial peptides (AMPs): a patent review.

Authors:  Hee-Kyoung Kang; Cheolmin Kim; Chang Ho Seo; Yoonkyung Park
Journal:  J Microbiol       Date:  2016-12-30       Impact factor: 3.422

7.  Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10.

Authors:  Dimitrios C Ziogas; Apostolos K A Karagiannis; Brenda M Geiger; Beatriz Gras-Miralles; Robert Najarian; Ofer Reizes; Leo R Fitzpatrick; Efi Kokkotou
Journal:  Peptides       Date:  2014-02-18       Impact factor: 3.750

8.  The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

Authors:  Karin Loser; Thomas Brzoska; Vinzenz Oji; Matteo Auriemma; Maik Voskort; Verena Kupas; Lars Klenner; Cornelius Mensing; Axel Hauschild; Stefan Beissert; Thomas A Luger
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

9.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

10.  Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells.

Authors:  Franco Capsoni; Anna Maria Ongari; Eva Reali; Anna Catania
Journal:  Arthritis Res Ther       Date:  2009-10-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.